Crinetics Pharmaceuticals
CRNX
247 hedge funds and large institutions have $5.1B invested in Crinetics Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 111 increasing their positions, 68 reducing their positions, and 22 closing their positions.
159% more call options, than puts
Call options by funds: $1.7M | Put options by funds: $654K
68% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 22
63% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 68
18% more capital invested
Capital invested by funds: $4.32B → $5.1B (+$775M)
17% more funds holding in top 10
Funds holding in top 10: 12 → 14 (+2)
5% more funds holding
Funds holding: 235 → 247 (+12)
1.89% more ownership
Funds ownership: 105.61% → 107.49% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$250M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$163M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$157M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$139M |
| 5 |
BlackRock
New York
|
+$54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$33.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$30.2M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$20M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$10.5M |
| 5 |
DFO
Duquesne Family Office
New York
|
-$10.4M |
CRNX Hedge Fund Activity: Q4 2024 in Review
247 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2024, worth a combined $5.1B — up 18% from $4.32B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new CRNX positions and 22 closed out — a net gain of 15 holders — while 111 added to existing stakes and 68 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $250M. The largest seller was Paradigm Biocapital Advisors, cutting an estimated $33.9M.
- 247 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2024, up from 235 in Q3 2024.
- Funds reported $5.1B of Crinetics Pharmaceuticals stock for Q4 2024, up 18% quarter-over-quarter.
- 37 funds opened new Crinetics Pharmaceuticals positions in Q4 2024 and 22 closed out, a net change of +15 holders.
- The largest Crinetics Pharmaceuticals buyer in Q4 2024 was Fidelity Investments, an estimated $250M added.
- The largest Crinetics Pharmaceuticals seller in Q4 2024 was Paradigm Biocapital Advisors, an estimated $33.9M sold.
Based on aggregated 13F filings for Q4 2024.